#### **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-QSB/A (Amendment No. 1)

# [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended March 31, 2001

OR

# [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 0-25238

NATURAL HEALTH TRENDS CORP.

(Exact Name of Small Business Issuer as Specified in its Charter)

Florida

59-2705336

State or other jurisdiction of incorporation or organization

(I.R.S. Employer Identification No.)

12901 Hutton Drive Dallas, Texas 75234 (Address of Principal Executive Office) (Zip Code)

(972) 241-4080

(Issuer's telephone number including area code)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

The number of shares of issuer's Common Stock, \$.001 par value, outstanding as of March 31, 2001 was 494,403 shares.

NATURAL HEALTH TRENDS CORP.

FORM 10-QSB/A

For Quarter Ended March 31, 2001

# **Explanatory Note:**

- -----

The purpose of this amendment is to amend Part I Item 2 - Management's Discussion and Analysis and Part I, Item 1 - Financial Statements for the restatements identified in note 2 to the consolidated financial statements and to give effect to the 1 for 100 reverse stock split in March 2003. All other items remain unchanged from the original filing.

During the quarters ended September 30 and December 31, 2003, the Company re-evaluated its financial statements for the years ended December 31, 2002 and 2001, the quarterly periods included in such years and the quarterly periods ended March 31, June 30 and September 30, 2003. As a result of such review, the Company determined that it inadvertently applied the incorrect accounting treatment with respect to the following items:

(i) revenue recognition with respect to administrative enrollment

C	
teec	٠

- (ii) revenue cut-off between 2002 and 2003;
- (iii) reserves established for product returns and refunds;
- (iv) the gain recorded in connection with the sale of a subsidiary in 2001; and
- (v) income tax provisions.

Consequently, the Company is amending and restating its financial statements for each quarter in 2001, 2002 and 2003 as well as the Form 10-KSB for the years ended December 31, 2001 and 2002.

# NATURAL HEALTH TRENDS CORP.

# FORM 10-QSB/A

For Quarter Ended March 31, 2001

# **INDEX**

Page Number			
PART I - FINANCIAL INFORMATION			
Item 1. Financial Statements (unaudited)			
Consolidated Balance Sheet as of March 31, 2001		1	
Consolidated Statements of Operations for the three months ended March 31, 2001 and 20	000		2
Consolidated Statements of Comprehensive Incorfor the three months ended March 31, 2001 and 20			3
Consolidated Statements of Cash Flows for the three months ended March 31, 2001 and 20	000		4
Notes to the Consolidated Financial Statements		5	
Item 2. Management's Discussion and Analysis or Plan Operations 8	ı of		
Item 3. Controls and Procedures	11		
PART II - OTHER INFORMATION			
Item 1. Legal Proceedings	12		
Item 2. Changes in Securities and Use of Proceeds		12	
Item 3. Defaults Upon Senior Securities		12	
Item 4. Submission of Matters to a Vote of Security Ho	olders		12
Item 5. Other Information	13		
Item 6. Exhibits and Reports on Form 8-K		13	
Signature 14			
Certifications 15			

NATURAL HEALTH TRENDS CORP.

CONSOLIDATED BALANCE SHEET

(UNAUDITED)

# 2001 As Restated

#### **ASSETS**

Current Assets:

\$ 528,987 Cash Account receivables 46,528 Restricted cash 66,944 Inventory 342,887

Prepaid expenses and other current assets

**Total Current Assets** 1,059,771

Property and equipment, net 39,418 Deposits and other assets 34,639

74,425

**Total Assets** \$ 1,133,828

# LIABILITIES AND STOCKHOLDERS' DEFICIT

Current Liabilities:

Accounts payable \$ 3,446,950 Accrued expenses 1,724,328 Accrued associate commissions 164,250 Notes payable 660,867 Current portion capital lease obligation 44,111 Deferred revenue 248,236

**Total Current Liabilities** 6,288,742

Capital lease obligations, net of current

portion 2,479

Long-term note payable 525,364

**Total Liabilities** 6,816,585

Stockholders' Deficit:

Preferred stock 5,343,509 Common stock 494 Additional paid in capital 24,287,728 Accumulated deficit (35,314,043)

Accumulated other comprehensive income (445)

Total Stockholders' Deficit (5,682,757)

Total Liabilities and Stockholders' Deficit \$ 1,133,828

The accompanying notes are an integral part of these consolidated financial statements.

# NATURAL HEALTH TRENDS CORP.

# CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months Ended March 31,

2001

As Restated 2000

\_\_\_\_\_

Net sales \$ 3,004,023 \$ 3,186,218 Cost of sales 573,820 682,197

-			
Associate commissions	1,666	,894 1,29	05,905
Selling, general and administrative exper	ises	743,655	1,234,110
Operating income (loss)	19,6	54 (25,9	994)
(Loss) gain on foreign currency		(44) 2,0 980) 26	641
Other (expense) income, net	(2,	980) 26	,149
Interest expense, (net)	(12,410	6) (6,91	4)
N. i. a. )	4 0 1 4	(4.110)	
Net income (loss)	4,214	(4,118)	
Preferred stock dividends	106 (	043 625	102
Freiened stock dividends		J43 023	,103
Net loss to common shareholders	s (	101,829) \$	(629 221)
	,	=======	
Basic loss to common shareholders	\$	(0.37) \$	(7.65)
======			====
Basic weighted common shares used		278,047	82,204
<del></del>			====
Dil . 11	ф	(0.0 <b>2</b> )	(7.65)
Diluted loss to common shareholders	\$	` ′	` ′
<del></del>			<del></del>
Diluted weighted common shares used		5 052 702	82 20 <i>4</i>
Diffused weighted common shares used		3,832,782	

2,430,203

2,504,021

The accompanying notes are an integral part of these consolidated financial statements.

2

Gross profit

# ${\tt NATURAL\ HEALTH\ TRENDS\ CORP.}$

# CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

	March 31,		
	2001 As Restated 2000		
Net income (loss)	\$ 4,214 \$ (4,118)		
Other comprehensive income, n Foreign currency	net of tax:		
translation adjustments	36,758		
Comprehensive income (loss)	\$ 40,972 \$ (4,118)		

The accompanying notes are an integral part of these consolidated financial statements.

3

NATURAL HEALTH TRENDS CORP.

(UNAUDI	TED)
<table> <caption></caption></table>	
	Three Months Ended March 31,
	2001 As Restated 2000
<\$> CASH FLOWS FROM OPERA	<c> <c></c></c>
Net income (loss)	\$ 4,214 \$ (4,118)
Adjustments to reconcile net inc cash provided by (used in) opera	
Depreciation and amortization	
Impairment of fixed assets Common stock issued for serv	35,448
interest/penalties	13,712 46
Changes in operating assets and	liabilities:
Accounts receivable	5,240 (428,607)
Inventories	(145,818) (269,915) rrent assets (56,833) 50,834 52,400 (75,949) 400,182 (47,420)
Deposits and other assets	52.400 (75.949)
Accounts payable	400,182 (47,439)
Accrued expenses(i)	227,118 331,833
Deferred revenue Other current liabilities	227,118 331,833 128,823 (527,831) (284,655) 59,848
Total Adjustments	377,800 (821,834)
NET TROVIDED DT (OSED IN	(823,732)
CASH FLOWS FROM INVEST	ING ACTIVITIES:
Capital expenditures	(20,921)
Decrease in restricted cash	(20,921) 5,890 32,838
NET CASH (USED IN) PROVI	DED BY INVESTING ACTIVITIES (15,031) 32,838
CASH FLOWS FROM FINANC Proceeds from preferred stock Proceeds from notes payable a Payments of notes payable and	
NET CASH PROVIDED BY FI	NANCING ACTIVITIES 16,827 634,545
Effect of Exchange rates	36,758
NET INCREASE (DECREASE)	IN CASH 420,568 (158,569)
CASH, BEGINNING OF PERIO	DD 108,419 434,063
CASH, END OF PERIOD	\$ 528,987 \$ 275,494 ===================================

  || (i) Certain accrued expenses were December 31, 2000. | e reclassified to notes payable and debt as of |
The accompanying notes are an integral part of these consolidated financial statements.

#### NATURAL HEALTH TRENDS CORP.

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

# THREE MONTHS ENDED MARCH 31, 2001

(UNAUDITED)

#### 1. Basis of Presentation

The accompanying unaudited financial statements of Natural Health Trends Corp. and its subsidiaries (the "Company") have been prepared in accordance with generally accepted accounting principles for interim financial information and with instructions to Form 10-QSB and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (consisting of normal recurring accruals) of financial position and results of operations for the interim periods have been presented. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Operating results for the three month period ended March 31, 2001 are not necessarily indicative of the results that may be expected for the year ending December 31, 2001. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2000.

NHTC's common stock, par value \$.001 per share (the "Common Stock"), is listed on the OTC Bulletin Board (the "OTCBB"). In March 2003, we effected a 1-for-100 reverse stock split with respect to our outstanding shares of Common Stock. In addition, the trading symbol for the shares of our Common Stock changed from "NHTC" to "NHLC". The effect of the reverse is reflected throughout this document.

# 2. Restatement of Previously Issued Financial Statements

During the quarters ended September 30 and December 31, 2003, the Company re-evaluated its financial statements for the years ended December 31, 2002 and 2001, the quarterly periods included in such years and the quarterly periods ended March 31, June 30 and September 30, 2003. As a result of such review, the Company determined that it inadvertently applied the incorrect accounting treatment with respect to the following items:

- (i) revenue recognition with respect to administrative enrollment fees;
- (ii) revenue cut-off between 2002 and 2003;
- (iii) reserves established for product returns and refunds;
- (iv) the gain recorded in connection with the sale of a subsidiary in 2001; and
- (v) income tax provisions.

Consequently, the Company is amending and restating its financial statements for each quarter in 2001, 2002 and 2003 as well as the Form 10-KSB for the years ended December 31, 2001 and 2002.

In connection with the engagement of a new independent accounting firm and the review of the Company's financial statements, the Company has revised its accounting treatment for administrative enrollment fees received from distributors in accordance with the principles contained in Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements", ("SAB 101") and related guidance. The Company determined that under SAB 101, such fees actually received and recorded as current sales in prior quarters should have been deferred and recognized as revenue on a straight-line basis over the twelve-month term of the membership. The restatement resulted in net

5

sales for the three month period ended March 31, 2001 being decreased by approximately \$182,000. The restatement in net sales resulted in a corresponding adjustment to cost of sales for direct costs paid to a third

party associated with the administrative enrollment fees received from distributors. Compared to amounts previously reported, the restatement decreased cost of sales by approximately \$65,000 for the three month period ended March 31, 2001.

In connection with the 2003 annual audit, the Company reviewed its revenue cut-off as of the beginning of 2003. There was no impact of this item to the 2001 financial statements.

The Company had not recorded a reserve for distributor returns and refunds as of September 30, 2003 and for prior periods. Based upon analysis of the Company's historical returns and refund trends by country, it was determined that the reserves for returns and refunds for prior quarters were required and should be recorded. The restatement resulted in no adjustment for the quarter ended March 31, 2001.

In 2001, the Company sold all of the outstanding common stock in Kaire Nutraceuticals, Inc. ("Kaire"), a Delaware corporation and wholly-owned subsidiary, to an unrelated third party. The gain on the sale of Kaire was approximately \$3.1 million, a portion of which was previously deferred. The Company subsequently recognized into income approximately \$1.9 million from the transaction over the period from the fourth quarter of 2001 through the second quarter of 2003. Based upon a review of the transaction, the Company now believes the gain on sale of Kaire should have been recognized only in 2001 and 2002 and not in 2003. The restatement resulted in no adjustment for the quarter ended March 31, 2001.

The Company disclosed in its 2002 Form 10-KSB that it had a net operating loss carry forward at December 31, 2002 of approximately \$6,000,000, subject to certain limitations. Consequently, the Company made no provision for income taxes for any period in 2002 or 2001. Upon further review, it has been determined that the available net operating loss was not expected to be sufficient to offset all of the domestic and foreign taxable income in 2002 or 2001. The restatement resulted in no adjustment for the quarter ended March 31, 2001.

The following table presents amounts from operations as previously reported and as restated (in thousands, except for per share data):

	Three Months Ended March 31, 2001					
	As Previously Reported		As	<b>.</b>		
Net sales Cost of sales		3,186 639		574		
Gross profit Operating expenses		2,547 2	7 ,411	2,43 	0 2,411	
Operating income Interest expense, other in loss on foreign exchange on discontinued operation	and gain		(15)		19 (15)	
Net income Preferred stock dividends	3		1 106		106	
Net income available to c stockholders	\$	15		,	2)	
Basic income per share			0.05		(0.37)	
Basic weighted common	shares u					278

Diluted income per share	\$	0.00	\$	(0.02)
Diluted weighted common sha	res used	== ==	5,85	3 5,853

6

#### Basic and Diluted Income per share:

The adjustments in net sales and cost of sales resulted in a net decrease in net income available to stockholders of approximately \$117,000 over the amounts previously reported for the three months ended March 31, 2001. Restated basic and diluted income per share decreased \$0.42 and \$0.02, respectively, for the three months ended March 31, 2001.

# 3. Principles of Consolidation and Accounting Policies

The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

#### Reclassifications

Certain reclassifications were made to the prior year financial statements to conform to the current year presentation.

#### Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the USA requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

# Revenue Recognition

The Company's revenues are primarily derived from sales of products, sales of starter and renewal administrative enrollment packs and shipping fees. Substantially all product sales are sales to associates at published wholesale prices. The Company defers a portion of its revenue from the sale of its starter and renewal packs related to its administrative enrollment fee. The Company amortizes its deferred revenue and its associated direct costs over twelve months, the term of the membership. Total deferred revenue for the Company was approximately \$248,000 as of March 31, 2001.

The Company also estimates and records a sales return reserve for possible sales refunds based on historical experience.

# Shipping and Handling Costs

The Company records freight and shipping revenues collected from associates as revenue. The Company records shipping and handling costs associated with shipping products to its associates as cost of goods sold.

# Earnings Per Share

Basic earnings per share is computed based on the weighted average number of common shares outstanding during the periods presented. Diluted earnings per share data gives effect to all potentially dilutive common shares that were outstanding during the periods presented.

7

# 4. Equity Transactions

During the first quarter of 2001, the Company received notice of conversion on of Series E, F, G, and H Preferred Stock. The Company issued 334,784 shares of common stock in settlement of the shares of Preferred Stock and the accrued dividends thereon. The following table sets forth the conversions and the stock price thereof as of the date of conversion.

Preferred stock Series		Preferred Stock Face	Common stock conversion
converted	Conversion	Date Valu	ie price
 Е	4-Jan-01	5,236	.01005
E	18-Jan-01	3,898	.0075
E	22-Jan-01	3,974	.00765
E	23-Jan-01	5,452	.0105
E	24-Jan-01	7,476	.0144
Е	8-Feb-01	6,990	.0129
Е	17-Feb-01	12,856	.01194
E	25-Mar-01	23,008	.010965
E	12-Mar-01	5,800	.01125
F	17-Feb-01	172,118	.02359
F	25-Mar-01	30,000	.019
G	17-Jan-01	16,000	.0095
G	27-Feb-01	13,000	.01425
G	26-Feb-01	21,000	.0114
G	25-Mar-01	14,400	.0114
G	31-Mar-01	17,000	.01235
Н	5-Feb-01	19,132	.0125
Н	31-Mar-01	31,561	.01000

#### ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

The following discussions should be read in conjunction with the consolidated financial statements and notes contained in Item 1 hereof.

# Forward Looking Statements

When used in Form 10-QSB and in future filings by the Company with the Securities and Exchange Commission, the words "will likely result", "the Company expects", "will continue", "is anticipated", "estimated", "projected", "outlook" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. The Company wishes to caution readers not to place undue reliance on such forward-looking statements, each of which speak only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected. The Company has no obligation to publicly release the results of any revisions which may be made to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.

8

# Overview

Prior to August 1997, the Company's operations consisted of the operations of the Natural Health Care Centers, and vocational schools. Upon the acquisition of Global Health Alternatives, Inc. ("GHA") on July 23, 1997, the Company commenced marketing and distributing a line of natural, over-the-counter homeopathic pharmaceutical products. In February 1999, the Company acquired the assets of Kaire International, Inc. and commenced marketing and distributing a line of natural, herbal based dietary supplements and personal care products through an established network marketing system.

The Company discontinued the operations of the Natural Health Care Centers during the third quarter of 1997 and sold the vocational schools in August 1998. During the fourth quarter of 1999, the Company ceased GHA activity and in March 2001 filed for Chapter 7 Bankruptcy in U.S. Federal Court, North Dallas. In January 2001 we launched Lexxus International, Inc., a majority owned subsidiary and commenced marketing and distributing a line of woman's topical creme that assists in sexual stimulation.

Results of Operations - Three Months Ended March 31, 2001 Compared To the Three Months Ended March 31, 2000.

As discussed in Note 2 to the consolidated financial statements, we have amended

and restated our results for the three month period ended March 31, 2001. All of the following analyses apply the basis of the restated amounts.

Net Sales. Net sales were approximately \$3,004,000 and \$3,186,000 for the three months ended March 31, 2001 and March 31, 2000. Sales for eKaire.com and Kaire Nutraceuticals declined approximately \$1,800,000 which was partially offset by sales of Lexxus International of approximately \$1,618,000 which was slightly reduced by the deferral of revenue related to the administrative enrollment fee of distributors.

Cost of Sales. Cost of sales for the three months ended March 31, 2001 was approximately \$574,000 or 19.1% of net sales. Cost of sales for the three months ended March 31, 2000 was approximately \$682,000 or 21.4% of net sales. The total cost of sales decreased by approximately \$108,000 or 15.8% due to lower costs associated with the Lexxus product line slightly offset by the deferral of the cost of sales related to the direct cost of the administrative enrollment fee of the distributors.

Gross Profit. Gross profit decreased from approximately \$2,504,000 in the three months ended March 31, 2000 to approximately \$2,430,000 in the three months ended March 31, 2001. The decrease was approximately \$74,000 or 3.0%. The decrease was attributable to the deferral of both revenue and cost of sales related to the administrative enrollment fee of distributors partially offset by higher sales volumes in our Lexxus subsidiary and its lower cost of sales per unit.

Associate Commissions. Associate commissions were approximately \$1,667,000 or 55.5% of net sales in the three months ended March 31, 2001 compared to approximately \$1,296,000 or 40.7% of net sales for the three months ended March 31, 2000. This increase is attributable to the Lexxus compensation plan.

Selling, General and Administrative Expenses. Selling, general and administrative costs decreased from approximately \$1,234,000 or 38.7% of sales in the three months ended March 31, 2000 to approximately \$744,000 or 24.8% of sales in the three months ended March 31, 2001, a decrease of approximately \$490,000 or 39.7%. The decrease is due primarily to eKaire's reduction of expenses and Lexxus sharing overhead in its start-up phase.

Operating Income (loss). Operating income (loss) increased from a loss of approximately \$26,000 in the three months ended March 31, 2000 to operating income of approximately \$20,000 in the three months ended March 31, 2001.

9

Other Income/Expense and Interest. Other income and interest of approximately \$19,000 or 0.6% of sales in the three months ended March 31, 2000 decreased to expense of approximately \$15,000 or 0.5% of sales in the three months ended March 31, 2001, a change of approximately \$34,000.

Income Taxes. Income tax benefits were not reflected in either period. The anticipated benefits of utilizing net operating losses against future profits was not recognized in the three months ended March 31, 2001 or the three months ended March 31, 2000 under the provisions of Financial Standards Board Statement of Financial Accounting Standards No. 109 (Accounting for Income Taxes), utilizing its loss carry forwards as a component of income tax expense. A valuation allowance equal to the net deferred tax asset has not been recorded, as management of the Company has not been able to determine that it is more likely than not that the deferred tax assets will be realized.

Net Income (Loss). Net income was approximately \$4,000 in the three months ended March 31, 2001 as compared to a loss of approximately \$4,000 in the three months ended March 31, 2000.

Liquidity and Capital Resources:

The Company has funded its working capital and capital expenditure requirements primarily from cash provided through borrowings from institutions and individuals, and from the sale of our securities in private placements. Our other ongoing source of cash receipts has been from the sale of eKaire.com and Lexxus products.

In February 1998, we issued \$300,000 face amount of Series B Preferred Stock, net of expenses of \$38,500. The Series B Preferred Stock has been converted into

In April 1998, we issued \$4,000,000 face amount of Series C Preferred Stock, net of expenses of \$492,500 from the proceeds raised, we paid \$2,500,000 to retire \$1,568,407 face value of Series A Preferred Stock outstanding. The Series C Preferred Stock has been converted into 36,083 shares of common stock.

In July 1998, we issued \$75,000 face amount of Series D Preferred Stock, which was redeemed in August 1998 for \$91,291.

In August 1998, we issued \$1,650,000 face amount of Series E Preferred Stock, net of expenses of \$210,500. The Series E Preferred Stock pays dividends of 10% per annum and is convertible into shares of common stock at the lower of the closing bid price on the date of issue or 75% of the market value of the common stock. In September 1999, \$610,000 of face amount of Series E Preferred Stock was converted into 6,031 shares of common stock.

In August 1998, we sold our three vocational schools and certain related businesses for \$1,778,333 and other consideration. From the proceeds from the sale of the schools, we paid \$1,030,309 to retire the remaining \$631,593 face value of Series A Preferred Stock then outstanding and \$91,291 to redeem all of the Series D Preferred Stock outstanding. The remaining proceeds were used to pay down payables.

In March and April 1999, we issued \$1,400,000 of Series H Preferred Stock. The Series H Preferred Stock pays dividends of 10% per annum and is convertible into shares of common stock at the lower of the closing bid price on the date of issue or 75% of the market value of the common stock. In the first quarter of 2001, 50,693 shares of Series H Preferred Stock were converted into 54,253 shares of the Company's common stock.

In June 1999, we borrowed \$100,000 from Domain Investments, Inc. The loan bears interest at 10% per annum and is payable on demand. The note is convertible into shares of common stock at a discount equal to 60% of the average closing bid price of the common stock on the three days preceding notice of conversion.

In July and August 1999 we borrowed \$150,000 from Filin Corporation, and issued a secured promissory note due on the earlier of 60 days from the date of issuance or upon the sale of its securities resulting in gross proceeds of at least \$5,000,000 and bearing interest at the rate of 10% per annum, but in no event less than \$12,000. In October 1999 we amended the promissory note to provide that the note is payable upon demand and is convertible into shares of common stock at a discount equal to 60% of the average closing bid price of the common stock on the three days preceding notice of conversion.

10

In October 1999, we borrowed \$100,000 from Domain Investments, Inc. The loan bears interest at 10% per annum and is payable on demand. The note is convertible into shares of common stock at a discount equal to 60% of the average closing bid price of the common stock on the three days preceding notice of conversion.

In November 1999, we borrowed \$70,000 from Domain Investments, Inc. The loan bears interest at 10% per annum and is payable on demand. The note is convertible into shares of common stock at a discount equal to 60% of the average closing bid price of the common stock on the three days preceding notice of conversion. This note was repaid with interest in March 2000.

During 2000, the Company did not make its payroll tax deposits with the Internal Revenue Service ("IRS") and the various state taxing authorities on a timely basis. The Company has filed all required payroll tax returns and is currently negotiating a payment plan with the IRS. As of March 31, 2001, the Company owed approximately \$816,000 of delinquent payroll tax liabilities including interest and penalties.

During 1999 and 2000, the Company did not make its sales tax deposits with the various sales tax authorities on a timely basis. The Company has filed all required sales tax returns. As of March 31, 2001, the Company owed approximately \$287,000 in current and delinquent sales taxes which is included in other current liabilities.

In March 2000, we sold 1,000 shares of Series J Preferred Stock with a stated

value of \$1,000 per share realizing net proceeds of \$1,000,000. The preferred stock pays a dividend at the rate of 10% per annum. The preferred stock and the accrued dividends thereon are convertible into shares of the Company's common stock at a conversion price equal to the lower of the closing bid price on the date of issuance or 70% of the average closing bid price of the common stock for the lowest three trading days during the twenty day period immediately preceding the date on which the Company receives notice of conversion from a holder. In connection with the offering of the Series J Preferred Stock, the Company issued warrants to purchase 1,419 shares of common stock at an exercise price of \$1.41 per share.

In February 2001, we borrowed \$50,000 from an individual. The loan bears interest at 12% per annum and is due in April 2001.

At March 31, 2001, our ratio of current assets to current liabilities was 0.17 to 1.0 and we had a working capital deficit of approximately \$5,229,000.

Cash provided by operations for the three months ended March 31, 2001 was approximately \$382,000. Cash used in investing activities during the period was approximately \$15,000, which primarily relates to capital expenditures. Cash provided by financing activities during the period was approximately \$17,000. Total cash increased by approximately \$421,000 during the period.

#### CRITICAL ACCOUNTING POLICIES

Management's discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the USA. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenue and expenses and disclosures at the date of the financial statements. We evaluate our estimates on an on-going basis, including those related to revenue recognition, legal contingencies and income taxes. We use authoritative pronouncements, historical experience and other assumptions as the basis for making estimates. Actual results could differ from those estimates.

# ITEM 3. CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the

11

Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our President and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

During the quarter ended September 30, 2003, the Company identified certain matters that resulted in the restatement of the Company's financial statements for the three months ended March 31, 2001, as set forth in Note 2 to the Consolidated Financial Statements.

Within ninety (90) days prior to the date of this report, the Company's President and Chief Financial Officer evaluated the effectiveness of the Company's disclosure controls and procedures. Based upon his evaluation and as a result, in part, of the matters noted above, the Company's President and Chief Financial Officer has concluded that the Company's disclosure controls and procedures (as defined in Rules 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1937, as amended) are effective, with the qualification that the restatements mentioned above were just recently identified and implemented for the three and nine months ended September 30, 2002. Management requires additional time to fully (i) assess their correction plan and (ii) implement appropriate enhancements to its controls and procedures, if and so warranted in the circumstances.

Since the date of his evaluation, there have been no significant changes to the Company's internal controls or other factors that could significantly affect

these controls.

#### PART II - OTHER INFORMATION

ITEM 1. Legal Proceedings

Not applicable.

ITEM 2. Changes in Securities and Use of Proceeds

The Company received 16 notices of conversion on its Series E Preferred Stock during the three months ended March 31, 2001 and redeemed \$74,690, face value in exchange for 73,706 shares of the Company's common stock.

The Company received 5 notices of conversion on its Series F Preferred Stock during the three months ended March 31, 2001 and redeemed \$202,118, face value in exchange for 111,240 shares of its common stock.

The Company received 10 notices of conversion on its Series G Preferred Stock during the three months ended March 31, 2001 and redeemed \$81,400, face value in exchange for 79,321 shares of its common stock.

The Company received 2 notices of conversion on its Series H Preferred Stock during the three months ended March 31, 2001 and redeemed \$50,693, face value in exchange for 54,253 shares of its common stock.

The Company increased the number of authorized shares to 500,000,000 common stock, par \$.001, in January 2001 by a majority vote of the Board of Directors in order to meet it's obligations with respect to convertible securities.

ITEM 3. Defaults Upon Senior Securities

Not applicable.

ITEM 4. Submission of Matters to a Vote of Security Holders

Not applicable.

12

ITEM 5. Other Information

Not applicable.

ITEM 6. Exhibits and Reports on Form 8-K

a) Exhibits

Not applicable.

b) Reports on Form 8-K

Not applicable.

13

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

# By: /s/ MARK D. WOODBURN

\_\_\_\_\_

Mark D. Woodburn President and Chief Financial Officer

Date: April 12, 2004

14

#### EXHIBIT 31.1

#### CERTIFICATION

- I, Mark D. Woodburn, do certify that:
- 1. I have reviewed this quarterly report on Form 10-QSB/A of Natural Health Trends Corp.;
- Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))-and have:
  - a. Designed such disclosure controls and procedures, or caused such
    disclosure controls and procedures to be designed under my supervision
    to ensure that material information relating to the registrant,
    including its consolidated subsidiaries, is made known to me by others
    within those entities, particularly during the period in which this
    report is being prepared;
  - Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - c. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
- 5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
  - All significant deficiencies in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ MARK D. WOODBURN

-----

Mark D. Woodburn
President and Chief Financial Officer

Date: April 12, 2004

#### EXHIBIT 32.1

# CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Natural Health Trends Corp. (the "Company") on Form 10-QSB/A for the period ending March 31, 2001 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Mark D. Woodburn, President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

# /s/ MARK D. WOODBURN

o, marz, woodbore,

Mark D. Woodburn President and Chief Financial Officer

April 12, 2004

16